High-dose intensity cyclophosphamide, epidoxorubicin, vincristine and prednisone by shortened intervals and granulocyte colony-stimulating factor in non-Hodgkin's lymphoma: a phase 11 study
1998

High-Dose Chemotherapy for Non-Hodgkin's Lymphoma

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): P Pronzato, R Lionetto, F Botto, F Pensal, A Tognoni

Primary Institution: Ospedale S. Andrea, La Spezia, Italy; Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

Hypothesis

Can the acceleration of chemotherapy cycles improve dose intensity in non-Hodgkin's lymphoma treatment?

Conclusion

The study demonstrated that accelerating chemotherapy cycles is feasible and can achieve the desired dose intensity without excessive toxicity.

Supporting Evidence

  • Eighteen out of twenty patients achieved the planned dose intensity.
  • Fifteen patients had objective responses, including eight complete responses.
  • Median survival for all patients was 24 months.

Takeaway

Doctors gave a special treatment to 20 people with a type of cancer to see if they could give stronger medicine more often without making them too sick, and it worked well.

Methodology

Patients received a combination of chemotherapy drugs every 14 days, with G-CSF support to help manage side effects.

Limitations

The study was limited by its small sample size and the lack of a control group.

Participant Demographics

Patients had intermediate- to high-grade non-Hodgkin's lymphoma, with a median age of 66 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication